Interstitial Lung Disease Trial, Recruiting NCT06751069 Sponsor: Mayo Clinic Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Interstitial Lung Disease Trial, Recruiting

NCT06751069
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with fibrotic interstitial lung disease (a type of scarring lung condition), of any specific subtype, whether currently receiving treatment or having received treatment in the past
  • People who have more than 10% scarring visible on a CT scan of the lungs
  • People who experience at least a moderate level of breathlessness in daily life, as measured by a standard questionnaire (confirm with trial site for exact score details)
  • People of any racial or ethnic background, including those who do not speak English (professional translators will be provided to help throughout the study)

Who may not be able to join:

  • People who are unable to walk due to a physical condition affecting the bones, joints, nervous system, or heart
  • People who have difficulty understanding or following instructions due to cognitive impairment
  • People who have completed a traditional, centre-based pulmonary rehabilitation program within the 3 months before being considered for the study
  • People who are receiving hospice or end-of-life care at the time of their screening assessment
  • People who are experiencing a sudden and significant worsening of their lung condition at the time of their screening assessment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Teng Moua, Mayo Clinic

Phone: 507-293-1989

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
3 March 2025
Est. completion
1 July 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

King's Brief Interstitial Lung Disease (K- BILD); Physical activity as measured by change in mean number of steps per day

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov